Literature DB >> 25691610

Institutional review of compliance with NCCN guidelines for breast cancer: lessons learned from real-time multidimensional synoptic reporting.

Titilayo O Adegboyega1, Jeffrey Landercasper1, Jared H Linebarger1, Jeanne M Johnson1, Jeremiah J Andersen2, Leah L Dietrich2, Collin D Driscoll2, Meghana Raghavendra1, Anusha R Madadi1, Mohammed Al-Hamadani2, Choua A Vang2, Kristen A Marcou2, Jane Hudak2, Ronald S Go2.   

Abstract

BACKGROUND: Variations exist in compliance with NCCN Guidelines. Prior reports of adherence to NCCN Guidelines contain limitations because of lack of contemporary review and incomplete listing of reasons for noncompliance.
PURPOSE: To assess institutional compliance and assist national quality improvement strategies through identifying valid reasons for noncompliance.
METHODS: Compliance with NCCN Guidelines was recorded prospectively using electronic synoptic templates for patients with newly diagnosed breast cancer treated at a single institution between January 2010 and December 2011. Compliance with NCCN Guidelines was recorded. The accuracy of real-time synoptic auditing methods compared with retrospective chart review and reasons for noncompliance was assessed. SAS 9.3 software was used for data analysis.
RESULTS: Compliance with NCCN Guidelines among 395 patients was 94% for initial staging evaluation, 97% for surgery, 91% for chemotherapy, 89% for hormone therapy, 91% for radiation therapy, 85% for follow-up, and 100% for determination of estrogen receptor/progesterone receptor and HER2 status. Age, comorbidities, and stage influenced guideline compliance. The most common reasons for noncompliance were patient refusal, patient choice after shared decision-making, and overuse of testing. Synoptic templated reporting was accurate in 97% patients.
CONCLUSIONS: High compliance with NCCN Guidelines was demonstrated. Reasons for noncompliance were identifiable. Compliance and nonadherence can be evaluated quickly with electronic synoptic reporting. This allows real-time action plans to address quality concerns and aids national risk adjustment for comparison and benchmarking.
Copyright © 2015 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2015        PMID: 25691610     DOI: 10.6004/jnccn.2015.0026

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  6 in total

1.  PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer.

Authors:  Honggeng Guan; Yang Lan; Yuqiu Wan; Qin Wang; Cheng Wang; Longjiang Xu; Yongjing Chen; Wenting Liu; Xueguang Zhang; Yecheng Li; Yongping Gu; Zemin Wang; Fang Xie
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

2.  Appropriate treatment receipt after breast-conserving surgery.

Authors:  K Guidolin; M Lock; K Vogt; J A McClure; J Winick-Ng; C Vinden; M Brackstone
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

3.  Identification of CD4+CD25+CD127- regulatory T cells and CD14+HLA-DR-/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer.

Authors:  Jinhu Wang; Jianhong Yang
Journal:  Biomed Rep       Date:  2016-05-27

4.  Regional differences in recommended cancer treatment for the elderly.

Authors:  Vivian Ho; Meei-Hsiang Ku-Goto; Hui Zhao; Karen E Hoffman; Benjamin D Smith; Sharon H Giordano
Journal:  BMC Health Serv Res       Date:  2016-07-15       Impact factor: 2.655

5.  Clinical decision trees support systematic evaluation of multidisciplinary team recommendations.

Authors:  Mathijs P Hendriks; Xander A A M Verbeek; Jeannette G van Manen; Sannah E van der Heijden; Shirley H L Go; Gea A Gooiker; Thijs van Vegchel; Sabine Siesling; Agnes Jager
Journal:  Breast Cancer Res Treat       Date:  2020-07-06       Impact factor: 4.872

6.  The Value of Serum Exosomal miR-184 in the Diagnosis of NSCLC.

Authors:  Shujun Li; Yanming Lin; Yanxia Wu; Hualin Chen; Zhong Huang; Muwen Lin; Jiali Dong; Yongcun Wang; Zhixiong Yang
Journal:  J Healthc Eng       Date:  2022-04-11       Impact factor: 3.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.